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The insufficient efficaciousness of most currently used anticancer drugs has prompted 
worldwide efforts to reduce toxic and resistance effects, improve overall bioavailability, 
and widen the therapeutic window. A particularly promising technology to this end rests 
on the concept of polymer-drug conjugation, in which the bioactive agent is bound to a 
meticulously designed macromolecular water-soluble carrier through a biofissionable 
link. 
Drug release in the cancerous cell, strongly pH dependant, proceeds hydrolytically in 
the acidic intracellular compartment, and this represents an advanced drug delivery 
method in cancer chemotherapy. 
The synthesis of water-soluble macromolecular anticancer drugs composed of a 
polymeric carrier to which the antineoplastic agents are tied via biodegradable 
hydrazone links were investigated in this project. 
Carriers were synthesized essentially by polyaddition and ring-opening methods, and 
polycondensation process was utilized, refined and routinely used. Polyaspartamides 
derived from polysuccinimide by aminolytic ring-opening was the parent carrier’s 
structure, allowing for: 
a) A non-immunogenic and non-toxic chain construction, which was amenable to 
biodegradation and ensured catabolic elimination of the duly fragment polymer 
upon drug release; 
b) A highly flexible backbone and the presence of intrachain-type or side group-
attached solubilizing groups, which ensured conjugate solution in aqueous media 
required for rapid dissipation in the central circulation system, even if the 
conjugated drug itself does not possess water solubility; and; 
c) The presence of functional groups as binding sites, represented by the hydrazone 
entity, which ensured drug attachment and release, was introduced by treatment 
of polysuccinimide with hydrazine hydrate under specially developed experimental 
conditions, followed by treatment with selected, functionally active amines 




Drug systems were modified so as to contain carbonyl functionality, the crucial reaction 
site in this hydrazone linking process, and bioactive aldehydes, such as 
ferrocenylpropenal. A cinnamaldehyde was the primary drug model. In order to illustrate 
the multidrug-binding capacity of the polyaspartamide type carriers, and at the same 
time ensuring target-specific drug delivery, folic acid, a potential cell entry facilitator, 
was co-conjugated to selected polymeric conjugate containing ferrocenylpropenal. Cell 
carrier and conjugate polymers were purified, fractionated by aqueous phase dialysis in 
membrane tubing with 12 000 – 14 000 molecular – mass cut - off, and isolated by 
freeze-drying in ultimate yields of 45 – 80 % as water-soluble materials; and they were 
structurally characterized by spectroscopic techniques. Inherent viscosities were in the 
range of 8 – 36 mL g-1. The resulting cinnamaldehyde, curcumin and iron contents of 
the conjugates were in the range of 4 - 7 %, 10 – 14 % and 1.5 – 2.8 % respectively. In 
vitro experiments done under buffered solution (performed in polymer laboratory of 
school of chemistry of the university of the Witwatersrand) showed the released of 
drugs in cancer cell's pH (pH<7). The results of these tests suggest that in acidic 
environment PSI-hydrazine carriers drugs systems can release active drug such as 
ferrocenylpropenal, and on the other hand the polymers drugs systems showed higher 
stabilities under neutral conditions. Therefore drugs released under pH control can play 
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